Table 1.
Study Sample Baseline Characteristics (N = 79)
| … | Whole Study Sample | Cannabidiol (N = 39) | Placebo (N = 40) | P Valuea |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Sex | … | … | … | .678 |
| Male | 55 (69.6) | 28 (71.8) | 27 (67.5) | … |
| Female | 24 (30.4) | 11 (28.2) | 13 (32.5) | … |
| Age (y, median [IQR]) | 54.6 [48.5–65.4] | 53.4 [48.0–60.3] | 56.5 [49.3–68.2] | .192 |
| Time since HIV infection (y, median [IQR]) | 18.9 [11.7–24.8] | 19.1 [12.9–24.2] | 16.8 [10.8–26.7] | .746 |
| Time since the first persistent undetectable HIV viral load (y, median [IQR]) | 12.2 [8.1–17.3] | 11.9 [9.2–17.3] | 12.2 [7.7–16.8] | .610 |
| CD4 cell count (cells/µL, median [IQR]) | 753 [563–930] | 763 [596–933] | 665.5 [555.5–923.5] | .436 |
| CD8 cell count (cells/µL, median [IQR]) | 696 [469–924] | 602 [455–878] | 732 [488.5–942.3] | .486 |
| CD4/CD8 cell count ratio (median, [IQR]) | 1.1 [0.7–1.6] | 1.2 [0.7–1.6] | 1.1 [0.7–1.6] | .314 |
| Antiretroviral treatments | … | … | … | … |
| Nucleoside reverse transcriptase inhibitors | 46 (58.2) | 20 (43.5) | 19 (57.6) | .216 |
| Nonnucleoside reverse transcriptase inhibitors | 43 (54.4) | 24 (55.8) | 15 (41.7) | .210 |
| Integrase inhibitors | 53 (67.1) | 29 (54.7) | 10 (38.5) | .174 |
| HIV viral load | … | … | … | .201 |
| <20 copies/mL | 74 (93.7) | 35 (89.7) | 39 (97.5) | … |
| ≥20 copies/mL | 5 (6.3) | 4 (10.3) | 1 (2.5) | … |
aWilcoxon-Mann-Whitney for continuous variables, chi-square, or Fisher exact test for categorical ones.
Abbreviation: IQR, interquartile range.